56 results
Main objective: To test the efficacy of thyroxine replacement for subclinical hypothyroidism (SCH) in older adults. Primary Objective: To determine multi-modal effects (quality of life; cognitive; musculoskeletal and cardiovascular) of levo-…
The primary study objective is to assess the proportion of patients who remain within the IGF-I age adjusted normal limits with pasireotide LAR (60 mg) monotherapy, after 24 weeks of treatment.Secondary study objectives are assessment of the…
1. Does Levothyroxine treatment for subclinical hypothyroidism give multi-modal benefits for the oldest old people with subclinical hypothyroidism?2. Are benefits seen across a wide range of outcomes, including prevention of cardiovascular disease,…
1. Normalization of the abnormal serum TH parameters and thereby improving the clinical condition of the AHDS patients2. Observation of changes in cognitive and motor function.
To evaluate the effects of intranasal oxytocin versus placebo on social behaviour and also on eating behaviour in children with PWS.
The purpose of this study is to look at the effect of changing from monthly (4 weekly) injections of your usual treatment (octreotide LAR) to less frequent treatment (once every 6 or 8 weeks) with lanreotide Autogel 120 mg injections. The study…
The purpose of this study is to evaluate whether thyroid hormone replacement therapy in type 2 diabetic patients suffering from overt hypothyroidism will improve muscular mitochondrial function, lower ectopic fat accumulation in muscle and liver,…
To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.
The primary objective is to investigate the efficacy, safety and tolerability of RV 001 (a fully human anti-IGF-1R antibody) administered q3W for 6 months, in comparison to placebo, in the treatment of patients suffering from active TED.Secondary…
The primary endopoint is to determine whether ketoconazole/octreotide combination therapy, followed by octreotide monotherapy, is an effective treatment for Cushing's disease. Secundary endpoints address the effects of this therapy on bone…
Primary objective: Assessment of the value of the short-term (2 weeks) response of IGF-I (peak IGF-I SDS) to GH in a dosage of 1.4 mg/m2/day (as part of a dose-escalation IGF-I generation test) in comparison to baseline IGF-I to predict the 1 year…
1. What are the effects of cinacalcet on clinical and biochemical parameters, including bone turnover markers, in patients with primary hyperparathyroidism due to a MEN-I mutation?2. What are the effects of cinacalcet on bone mineral density and…
Establishment whether usage of high viscosity PMMA bone cement in PVP for OVCFs leads to a reduction in leakage incidence compared to usage of conventional (low-medium) viscosity PMMA bone cement in PVP for OVCFs.Since evidence is scarce or…
The primary objective is to evaluate health related QoL under an oral sequential treatment with natural steroid hormones: Duogestan®. The secondary objective is to evaluate the bleeding patterns over a one-year period.
The primary objective of this study is to assess the effect of individualizing the growth hormone dose versus standard treatment with 1 mg/m2/day on adult height and the first and five year growth response. Secondly, we want to assess the long term…
Evaluating the efficacy and safety of sunitinib in patients with progressive, advanced/metastatic well-differentiated, unresectable pancreatic neuroendocrine tumors.
Objective: Main objective of this study is to compare the area under the MPH saliva concentration versus time curve (AUC) following ingestion of immediate and sustained release formulations of MPH in children with ADHD. Secondary objectives are: 1.…
The primary objective of this study is to assess the objective response rates (ORR) for two starting doses of vandetanib, 150 mg and 300 mg in patients with unresectable locally advanced or metastatic MTC having progressive or symptomatic disease.…
To investigate if sunitinib has clinical significant activity in patients with metastatic/recurrent paraganglioma/pheochromocytoma.
The primary objective of this study is to assess the effect of individualizing the growth hormone dose versus standard treatment with 1 mg/m2/day on adult height. Secondly, we want to assess the first and five year growth response, the long term…